Table of Contents

Section I: General Information

Chapter 1: The Drug Development Continuum, Preclinical to Market Access 3
Darlene (Dar) Rosario, MBA, BS, RAC-US; Pragnesh Donga, MPharm, MBA, RAC-Drugs; Kathrin Schalper, PhD, RAC-Devices, RAC-US, RAC-CAN, RAC-EU

Chapter 2: International Harmonization via ICH, WHO, and Other Global Initiatives 19
Linda McBride, RPh, RAC-US

Section II: Nonclinical Studies

Chapter 3: Principles of Good Laboratory Practice and Nonclinical Development 27
Neel Kamal Sharma, PhD, MS; Jennifer G. Brown, PhD, RAC-US

Chapter 4: Safety Pharmacology Studies 37
Charlene F. Barroga PhD, DABT; Brian M. Roche, PhD, DSP, DABT; Simon Authier, DVM, PhD, MBA, MSc, DSP

Chapter 5: Pharmacokinetic and Toxicokinetic Studies 53
Tyler Vandivort, PhD, DABT, RAC-Drugs; Dhanraj Deshmukh, PhD, DABT

Chapter 6: Acute and Chronic Toxicity Assessments 65
Charles Lambert, PhD, DABT, ERT; Brante P. Sampey, PhD, DABT

Chapter 7: Local Tolerance Studies 77
Ramesh Subramani, DVM, DABT, ERT, DSP, RAC-US

Chapter 8: Genotoxicity Studies 83
Tyler Vandivort, PhD, DABT, RAC-Drugs; Ramesh Subramani, DVM, DABT, ERT, DSP, RAC-US

Chapter 9: Carcinogenicity Studies 95
Tyler Vandivort, PhD, DABT, RAC-Drugs; Kalaiselvan Ponnusamy, MVSc, DIBTP, DICVP, DABT

Chapter 10: Developmental and Reproductive Toxicity Assessments 107
Charlene F. Barroga, PhD, DABT; Alan M. Hoberman, PhD, DABT, ATSF

Chapter 11: Regulatory Environmental Risk Assessment of Human Pharmaceuticals 121
Margaret L. Fleming, PhD; Sagar Thakali, PhD, IBERA; Jennifer K. Saxe, PhD, MBA

Section III: Chemistry, Manufacturing, and Controls

Chapter 12: The Global Regulatory Process for the Registration of Active Substances 137
Darlene (Dar) Rosario, MBA, BS, RAC-US; Yuwei Zhang, MD, PhD, MPH, MBA; Robert Falcone, PhD, FTOPRA, FRAPS

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Chapter 13: Biologics and Small Molecules 151
Ben McLaughlin, MSE

Chapter 14: Coordinating Drug Supply for Clinical and Nonclinical Development 163
Ajay Babu Pazhayattil, DBA, MPharm, CPGP

Chapter 15: Pharmaceutical Development Studies and Manufacturing Experience 173
Komalkumar Patel, MS; Nikolaos Zacharias, MS; Kingman Ng, PhD; Beat U. Steffen, MSc, MBA, RAC-Devices, FRAPS; Ricki A. Chase, MS; Nicole Beard, PhD, MSc

Chapter 16: Analytical Method Lifecycle: Management, Practice, and Regulatory Integration 201
Nidhi Kotecha, PhD, MPharm, RAC-Drugs; Siegfried Schmitt, PhD

Section IV: Clinical Trials

Chapter 17: Conducting Clinical Trials: Drug Application Types, Data Requirements, and Obtaining Marketing Approval 217
Sharry Arora, MPharm, MTOPRA, RAC-Drugs

Chapter 18: Phases of Development (1, 2, 3, 4) 229
Rowena Cook, MS, RAC-Global, RCC-IVDR; Siegfried Schmitt, PhD

Chapter 19: Enhancing Diversity in Clinical Trials 257
Monique J. Carter, MS, FRAPS; Zaida Recinos-Vasquez, MS, MS; Leonor Saldanha, PhD, MS; Jennifer Duru, PharmD

Chapter 20: Health Authority Interactions 275
Jewell D. Martin, MBA, MA, PMP, RAC-US; Marcello Milano, MSc; Angela W. Corona, PhD

Chapter 21: Pediatrics 297
Karl-Heinz Huemer, MD, PhD; Linda McBride, RPh, RAC-US

Chapter 22: Region-Specific Studies 313
Consuela Stewart

Section V: Marketing Authorization

Chapter 23: Core Labeling: An Important Global Tool 329
Cathleen A. O'Connell, PhD, MS, RPh; Stephanie Turri Lockman, MS

Chapter 24: Framework for Benefit-Risk Assessment 335
Cristina Damatarca, MD, PGD

Chapter 25: eCTD and Digital Applications 349
Danini Y. Marin, MSc; Katelyn Jean Mulligan, EMBA, MS

Chapter 26: Expedited Approval Pathways 359
Yingying Liu, MSc

Chapter 27: Dossier Requirements 401
Jesshanie Tabaniag; Kholoud M. Abdelfattah, MSc, CSRT-HMS; Danini Y. Marin, MSc; Salah Shawky, DrBA; Hannah Jin, BSc; Brix Gil Bayuga, RPh

Chapter 28: Combination Products 449
Beat U. Steffen, MSc, MBA, RAC-Devices, FRAPS; Ricki A. Chase, MS

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Section VI: Postmarketing Authorization

Chapter 29: Postauthorization Commitments 467
Karin McIntosh, MPharm, RAC-Drugs

Chapter 30: Transfers and Renewals 477
Pallavi Trivedi, MPH; Rudradutt Singh Vaghela, PhD, RAC-Drugs

Chapter 31: Product Extensions, Variations, and Supplements 495
Karin McIntosh, MPharm, RAC-Drugs

Chapter 32: Compliance 517
Siegfried Schmitt, PhD; Barbara A. Rusin, MS

Chapter 33: Recalls 531
Siegfried Schmitt, PhD

Chapter 34: Postmarket Surveillance 535
Pallavi Trivedi, MPH; Siegfried Schmitt, PhD; Cansın Gevrek, BS

Chapter 35: Advertising and Promotion 551
Timothy A. Candy, PharmD, MS, BCPS; Sue Duvall, MPA, RN, BS; Kathleen Grim, MS; Rebecca Lalani, PharmD

Chapter 36: Market Access: Reimbursement and Pricing 567
Pallavi Trivedi, MPH; Rudradutt Singh Vaghela, PhD, RAC-Drugs

Glossary, Abbreviations, and Acronyms 603

Index 637

Case Studies

Case Study 4-1 46
Case Study 4-2 47
Case Study 5-1 61
Case Study 10-1 117
Case Study 11-1 130
Case Study 19-1 269
Case Study 19-2 271
Case Study 19-3 272
Case Study 22-1 314
Case Study 22-2 314
Case Study 22-3 317
Case Study 22-4 318
Case Study 22-5 319
Case Study 22-6 320
Case Study 26-1 394
Case Study 35-1 562

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Figures

Figure 1-1. The Medicinal Product Development Continuum 4
Figure 1-2. Traditional de Novo Product Development Process Versus Product Repurposing 5
Figure 1-3. Phase Transition Duration From Phase 1 Through NDA/BLA Authorization 6
Figure 1-4. Phases of Clinical Research 10
Figure 1-5. CTD Triangle 12
Figure 1-6. Communicating Value to Healthcare Stakeholders 14
Figure 1-7. Relationship Between Pricing, Reimbursement, and Market Access 14
Figure 2-1. ICH Process of Harmonization 21
Figure 4-1. Continuum of Safety Pharmacology Assessments From Acute to Chronic Toxicity Studies 45
Figure 5-1. Drug Exposure Parameters Derived From PK Data 54
Figure 6-1. Phase-Appropriate Nonclinical Development Plan From Acute Studies Through Chronic Toxicity Studies 67
Figure 8-1. Decision Tree for Follow-Up Testing with an Ames-Positive Drug (Active Ingredient) 91
Figure 9-1. Genotoxic Versus Nongenotoxic Dose-Response Curves 96
Figure 9-2. ICH S1B(R1) Schema for Determining the Added Value of a 2-Year Carcinogenicity Study 103
Figure 10-1. Stages of the Reproduction and Development Cycle (A to F) as Described in ICH S5(R3) 108
Figure 10-2. Scheme for Fertility and Early Embryonic Development Studies, Embryofetal Development Studies, and Combined Studies 108
Figure 10-3. Scheme for Pre- and Postnatal Development Studies and Enhanced Studies 109
Figure 10-4. Scheme for Enhanced Pre- and Postnatal Development Studies in Rabbits for Vaccines2 116
Figure 10-5. Scheme to Determine If Standard Models for Hazard Assessment of Developmental Toxicity Can Be Used for Molecules That Produce Anti-Drug Antibodies 117
Figure 11-1. FDA Categorical Exclusion for Drug Approval – Small Molecules 122
Figure 11-2. FDA Studies Required for Drug Approval 123
Figure 11-3. EU ERA Process for Drug Approval 125
Figure 11-4. FDA Categorical Exclusion for Drug Approval – Biologics 129
Figure 12-1. Percentage of World Pharmaceutical Market by Economic Bloc 138
Figure 12-2. Brazil's API Background Regulations 145
Figure 12-3. China's API Registration Procedure 147
Figure 12-4. Japan's API Process Review 148
Figure 14-1. Clinical Supply 165
Figure 14-2. Routine Challenges in Clinical Supply 167
Figure 14-3. US-Marketed Products API Supply 167
Figure 14-4. Example Sample Kit Label and Bottle Label 169
Figure 15-1. Product Requirements 174
Figure 15-2. Factors Impacting Product Requirements – Ishikawa (Fishbone) 174
Figure 15-3. QbD Elements Flow Chart 175
Figure 15-4. Possible Leachables From a Plastic Bottle 185
Figure 15-5. Overview of Different Combination Product Categories 192
Figure 16-1. Analytical Method Lifecycle 202
Figure 18-1. Clinical Trial Lifecycle 231
Figure 18-2. Russian Approval Process 243
Figure 19-1. Contributing Factors of Clinical Trial Underrepresentation 258
Figure 19-2. Demographic Diversity of Global Clinical Trials Participation for New Drugs Approved by the FDA 258
Figure 19-3a. Distribution of Clinical Trial Participants: US Compared to the Rest of World 259
Figure 19-3b. Global Distribution of Clinical Trial Participants by Country Versus US 259
Figure 19-4. Clinical Trial Sex, Race, Age, and Ethnicity Distribution in the US 260
Figure 19-5. Percentage of Trials With Participant Levels Above Census 261
Figure 19-6. Representation in Pfizer Trials Versus US Census Level 261
Figure 19-7. OMB Minimum of Race and Ethnicity Categories 263
Figure 19-8. Intrinsic and Extrinsic Ethnic Factors 268
Figure 20-1. CHMP Scientific Advice Process 282
Figure 22-1. Requests for Local Clinical Data and Different Therapeutic Areas 314

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Figure 22-2. Representative Schematic of Potential Approaches to Conducting Regional-Specific Studies 315
Figure 22-3. Clinical Development Strategies Employing Local vs. MRCT Strategies 316
Figure 24-1. Continuous Benefit-Risk Assessment for Defining and Maintaining the Safety Profile of Drugs Through the Development Lifecycle 336
Figure 24-2. BRAT Six-Step Process 341
Figure 24-3. EMA Eight-Step PrOACT-URL 342
Figure 24-4. FDA's Benefit-Risk Framework for New Drug Review 342
Figure 26-1. Outcome of PRIME Eligibility Requests by Therapeutic Area 364
Figure 26-2. Expedited Pathways in Different Development Stages in China 372
Figure 26-3. Standard Marketing Authorization Application Procedures and Expedited Pathways 372
Figure 26-4. General Timeframe of SAKIGAKE 379
Figure 26-5. SAKIGAKE Designation Procedure 379
Figure 26-6. Standard Review, Conditional Early Pathway, Priority Review, and Orphan Drugs in Japan 380
Figure 26-7. Conditional Early Pathway Procedures in Japan 380
Figure 27-1. ASEAN CTD 414
Figure 28-1. Overview of Different Combination Product Categories 452
Figure 28-2. Argentinian Regulatory Pathway 461
Figure 32-1. How Good Practices Align with the Product Lifecycle 518
Figure 32-2. China Drug Regulatory Legislative System 525
Figure 32-3. China Drug Regulatory Landscape 526
Figure 33-1. Recall of Clinical Trial Supplies Process Flow 533
Figure 34-1. Possible Decisions During the Signal Evaluation Process 539
Figure 34-2. Benefit-Risk Management Cycle of the Medicinal Product 540
Figure 35-1. Example of a Reminder Ad 553
Figure 35-2. Example of a Reminder-Like Ad for a Drug with a Boxed Warning 553
Figure 35-3. General Timeline View of Presubmission Requirements for Subpart E/H Products 554
Figure 35-4. Issuance of Enforcement Action Letters Over Time (1997–2024) 559
Figure 36-1. Factors Influencing Medicinal Product Pricing 568
Figure 36-2. Process Map for France 570
Figure 36-3. Process Map for Germany 571
Figure 36-4. Mean Length of Time From EMA Authorization to HTA Decision for Oncology Products 573
Figure 36-5. Overview of ERP Across Europe (2013) 574
Figure 36-6. Types of Cost Containment Policies Adopted by Member States 575
Figure 36-7. Process Map for England 578
Figure 36-8. Process Map for Scotland 579
Figure 36-9. Timeline of US HTA-Like Bodies 583
Figure 36-10. Overview of the Canada Public System Reimbursement Decision Pathway 585
Figure 36-11. Map of Australian Government HTA Processes for Market Entry and Reimbursement Processes 590
Figure 36-12. Framework for Pricing Drugs and Devices in Japan 592
Figure 36-13. Flow Diagram of HTA in South Korea 593
Figure 36-14. Historical MaHTAS Milestones 593

Tables

Table 1 1. Pharmacology Studies – Overview 8
Table 1 2. Toxicology Studies – Overview 8
Table 2-1. Current Members and Observers of the ICH Association 20
Table 3-1. ALCOA+ Principles of Good Documentation Practice 30
Table 3-2. Final Study Report Items 31
Table 4-1. Cardiac Ion Channels Assessed by In Vitro Assay in Chinese Hamster Ovary (CHO) Cells and Human Embryonic Kidney 293 (HEK293) Cells 38

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Table 4-2. CV Study Designs and End Points ... 39
Table 4-3. Stand-Alone CV or Combined Cardio-Respiratory Telemetry Studies – Latin Square (4x4) Study Design ... 40
Table 4-4. Integrated CV or Cardio-Respiratory Telemetry End Points in a Nonrodent, Repeat-Dose, Toxicology Study Design ... 41
Table 4-5. Stand-Alone Rodent Respiratory or CNS (FOB or modified Irwin) Parallel Study Design ... 42
Table 4-6. Combined Respiratory and CNS (FOB or modified Irwin) Study in Rodent Repeat Dose Toxicology Study Design ... 42
Table 4-7. Safety Pharmacology Strategies for Pharmaceuticals and Biopharmaceuticals ... 44
Table 5-1. Parameters for Comparing Drug Exposure Across Studies ... 55
Table 5-2. Global Implementation of Major ICH Guidance Relevant to Pharmacokinetic and Toxicokinetic Studies ... 56
Table 5-3. Preclinical Case Study: ZILRETTA ... 61
Table 6-1. International Regulatory and Guidance Documents ... 66
Table 6-2. Standard List of Clinical Chemistry Parameters Evaluated in GLP Toxicology Studies ... 69
Table 6-3. Standard List of Clinical Chemistry Parameters Evaluated in GLP Toxicology Studies ... 70
Table 6-4. Common Species Used in General Toxicology Studies ... 73
Table 7-1. Maximum Applicable Volume (mL) for Local Tolerance Testing of Parenteral Drugs in Two Commonly Used Animal Models ... 79
Table 7-2. Study Design for Single Dose Subcutaneous Local Tolerance Study in Male New Zealand White Rabbits ... 80
Table 7-3. Testing Procedures for Local Tolerance Testing ... 81
Table 8-1a. ICH S2(R1) Recommendations for In Vitro Genotoxicity Testing ... 85
Table 8-1b. ICH S2(R1) Recommendations for In Vitro Genotoxicity Testing ... 86
Table 8-2a. ICH S2(R1) Recommendations for In Vivo Genotoxicity Testing ... 87
Table 8-2b. ICH S2(R1) Recommendations for In Vivo Genotoxicity Testing ... 87
Table 8-3. Overview of Common In Vitro and In Vivo Genotoxicity Testing Assays ... 89
Table 9-1. Global Implementation of Major ICH Guidance on Carcinogenicity ... 97
Table 9-2. Key Weight of Evidence Factors for Integrated Assessments of Carcinogenic Potential ... 104
Table 10-1. DART Strategy for Pharmaceuticals and Biologics Depending on Relevant Species ... 111
Table 10-2. Embryofetal Development Study Design Parameters for Rodent, Rabbit and Nonhuman Primate Species ... 111
Table 10-3. Considerations for the Design of an Enhanced Pre- and Postnatal Development Toxicity Study in Nonhuman Primates ... 113
Table 10-4. Considerations for Design of a Pre- and Postnatal Development Toxicity Study in Rats ... 114
Table 10-5. Potential Species for DART Studies ... 115
Table 11-1. Studies Required During the EU Environmental Risk Assessment Process ... 126
Table 12-1. Global Regulatory Active Substances Filing Requirements ... 139
Table 12-2. Master File Classifications ... 142
Table 12-3. Type of Fee (Active Substance Manufacturers) ... 144
Table 12-4. Type of Fee (Active Substance Importers and Distributors) ... 144
Table 13-1. Differences and Similarities in Manufacturing Information Provided in Commercial Product Applications ... 156
Table 13-2. Elucidation of Structure Requirements Based on ICH Guidelines: Q6A and Q6B ... 157
Table 13-3. Impurities Requirements Based on ICH Q3A, Q3C, Q5C, Q6A, and Q6B and Applicable National Health Authority Guidance ... 157
Table 13-4. Representative Analytical Methods and Rationale Recommended by ICH Q6A and Q6B and ATMP Guidance ... 158
Table 14-1. Components of Clinical Supply Chain Strategy ... 164
Table 14-2. Clinical Development Stages ... 164
Table 14-3. Comparing Clinical and Commercial Supply ... 166
Table 15-1. Comparison of Regulatory Guidance Based on Quality by Design Principles in Major Markets ... 176
Table 15-2. Summary and Comparison of Artificial Intelligence Guidance in Global Markets Related to Pharmaceutical Development ... 180
Table 15-3. Container Content/Volume Label Claim/Extractable Volume Test Regional Comparison ... 181
Table 15-4. Dosage Form Compatibility Cases ... 184
Table 15-5. Typical Packaging Suitability Considerations for Common Classes of Drug Products ... 184
Table 15-6. Extent and Design of Interaction Studies ... 185
Table 15-7. Dissolution Test Methods Most Commonly Used ... 186
Table 15-8. Biopharmaceutics Classification System ... 187
Table 15-9. Considerations for Specific Dosage Forms ... 187
Table 15-10. Most Common Routes of Administration: Advantages and Disadvantages ... 188

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Table 15-11. Comparison of Agency Guidelines on Multidose Presentations 190
Table 15-12. Regulatory Requirements and Guidance for Combination Products in Key Geographical Areas 191
Table 17-1. Key Documents Required for Clinical Trial Application Submission: US 219
Table 17-2. Changes to EU Legislation for the Conduct of Clinical Trials, 2022 to 2025 219
Table 17-3. Key Documents Required for Initial Clinical Trial Application Submission: EU 220
Table 17-4. Data Requirements for Clinical Investigation Stage: BRICS, APAC, and MENA Countries 222
Table 17-5. Comparison of Data Requirements for Marketing Application Stage: BRICS, APAC, and MENA Countries 222
Table 18-1. Phase I–IV Clinical/Regulatory Terminology 230
Table 18-2. APAC Countries and Respective Regulatory Authorities 245
Table 18-3. Middle East/North Africa Countries and Respective Regulatory Authorities 249
Table 18-4. Countries of Africa and Their Respective Regulatory Authorities 251
Table 19-1. US Clinical Trial Participant Cross-Section Distribution by Sex, Race, and Age for Select Therapeutic Areas 260
Table 19-2. Percentage of Pfizer Studies with Patient Participation at or Above US Census Levels Across Therapy Areas 262
Table 19-3. FDA Diversity Action Plan Elements 266
Table 19-4. Government of Canada Historical GBA Plus Initiatives and Activity Timeline 267
Table 20-1. Formal Meetings Negotiated Under PDUFA (Timelines) 277
Table 20-2. Formal Meetings Negotiated Under BsUFA (Timelines) 278
Table 20-3. CDA-AMC Scientific Advice Process 281
Table 20-4. CDA-AMC Scientific Advice at a Glance 281
Table 20-5. Key Timelines for CDA-AMC Scientific Advice Offerings 282
Table 20-6. Types of Questions for EMA Scientific Advice 283
Table 20-7. Parallel Scientific Advice Timelines 284
Table 20-8. EU/EEA National Competent Authorities and Scientific Advice 285
Table 20-9. Simultaneous NCA Participating Countries, Second Phase Pilot 290
Table 20-10. PMDA Categories and Content of Consultations for New Medicinal Products 293
Table 21-1. Comparison of Pediatric Development Regulations 310
Table 22-1. Time to Regulatory Authority and Ethics Board Approvals in an MRCT 320
Table 22-2. Clinical Trial Applications in North America (Canada, US) 321
Table 22-3. Clinical Trial Applications in Europe (EU, Switzerland, UK) 321
Table 22-4. Clinical Trial Applications in BRICS Countries 322
Table 22-5. Clinical Trial Applications in LATAM Countries 322
Table 22-6. Clinical Trial Applications in Asia 323
Table 22-7. Clinical Trial Applications in Oceania 323
Table 22-8. Clinical Trial Applications in Select MENA Countries 324
Table 23-1. Distinctions Between Core Labeling and Regional and Local Data Sheets 330
Table 23-2. Sample Structure of a CCDS Based on EU SmPC Headings 331
Table 23-3. Possible Reasons for Discrepancies Between Local Labeling and Core Labeling 333
Table 24-1. A Brief History of the Evolving BRA Initiatives, Methods, and Procedures 338
Table 24-2. UMBRA Steps and Process 343
Table 25-1. Advantages and Disadvantages of Electronic Versus Paper-Based CTD Applications 350
Table 25-2. Error Severity 355
Table 25-3. eCTD 4.0 Implementation Schedule as per ICH Guideline 356
Table 26-1. Overview of Expedited Approval Programs in the US 361
Table 26-2. Overview of Expedited Approval Pathways in Argentina 362
Table 26-3. Overview of Expedited Approval Pathways in Canada 362
Table 26-4. Overview of Expedited Approval Pathways in Mexico 363
Table 26-5. Comparison of Conditional Marketing Authorization and Marketing Authorization Under Exceptional Circumstances 365
Table 26-6. Overview of Accelerated Approval Pathways in the EU, Switzerland, the UK, and Turkey 368
Table 26-7. Overview of Expedited Approval Pathways in Brazil 370
Table 26-8. Summary of Expedited Approval Pathways in India 371
Table 26-9. Overview of Expedited Approval Pathways in China 373
Table 26-10. Overview of Expedited Approval Pathways in Australia 374

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

Table 26-11a. Overview of Expedited Approval Pathways in Japan: SAKIGAKE, Conditional Early Pathway and Priority Review 375
Table 26-11b. Overview of Expedited Approval Pathways in Japan: Orphan Drug Review, Recruitment for Unapproved Drugs and Indications, and Emergency Approval 377
Table 26-12. Overview of Expedited Approval Pathways in South Korea 381
Table 26-13. Overview of Expedited Approval Pathways in New Zealand 382
Table 26-14. Overview of Expedited Approval Pathways in Taiwan 385
Table 26-15. Overview of ASEAN Joint Assessment Procedure 387
Table 26-16. Overview of Approval Pathways in Brunei 388
Table 26-17. Overview of Expedited Pathways in Cambodia 388
Table 26-18. Overview of Expedited Regulatory Pathways in Indonesia 389
Table 26-19. Orphan Drug Designation in Malaysia 390
Table 26-20. Expedited Regulatory Pathways in Malaysia 390
Table 26-21. Overview of the Expedited Regulatory Pathways in Philippines 392
Table 26-22. Overview of Expedited Pathways in Singapore 393
Table 26-23. Eligible Criteria for a Drug to be Considered on the List of Rare Drugs in Vietnam 395
Table 27-1. Country Requirements 402
Table 27-2. Regulatory Authority and Country Legal Framework 407
Table 27-3. Content and Format Requirements 412
Table 27-4. Translation Requirements 419
Table 27-5. Dossier Requirement for Collaborative and Reliance Procedures 424
Table 27-6. Country-Specific Dossier Requirements Related to Selected Described Pathways 425
Table 27-7. Combination Product Definitions 435
Table 27-8. Combination Product Definitions in Additional Regions 437
Table 28-1. Examples of the Different Combination Product Categories 452
Table 28-2. Summary of Regulation of Combination Products in Several Asian Jurisdictions 459
Table 28-3. LATAM Recognition 460
Table 29-1. Regulatory Framework for Postauthorization Studies in Major America Regions 468
Table 29-2. Regulations and Guidance Documents in China 474
Table 31-1. Americas: Comparison of Regulations Across Jurisdictions 496
Table 31-2. NMRAs and Guidelines for Pharmaceuticals in African Countries 510
Table 32-1. Regulations and Guidance for GPvP Management and Reporting 519
Table 32-2. PRAC Scope of Recommendations 522
Table 32-3. EU Mutual Recognition Agreements 523
Table 34-1. MAH Reporting Requirements 537
Table 36-1. Summary of Time From EMA Authorization to HTA Decision and Outcome 572
Table 36-2. Overview of Reference Pricing and Country Baskets in Europe 575
Table 36-3. HTA and Associated Organizations in Selected EU Member States and the UK 580
Table 36-4. Comparison of HTA in Germany, France, UK, Italy, and Spain 581
Table 36-5. Drugs Eligible for CADTH's Drug Review Processes 583
Table 36-6. Summary of CADTH's Elements and Recommendation Categories 584
Table 36-7. Regulatory Authorities of the BRICS Region and Their Product Categories for Controlled Pricing 585
Table 36-8. Types of Drug Categories Followed in Brazil for Price Fixation 586
Table 36-9. Types of Regulatory Programs and Reimbursement Methods in Russia 587
Table 36-10. Summary of HTA Status in Select Asian Countries 589
Table 36-11. Selected Products for Japan's MHLW 3-Year HTA Pilot Evaluation 591
Table 36-12. MaHTAS 1995–2018 Impact Overview 594
Table 36-13. Regulatory Authorities and Pricing Models in South Asia 595

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org

SECTION

I General Information

Purchased from RAPS Library (library.raps.org) for the exclusive use of unknown.
© 2026 RAPS Library. Please report unauthorized use to raps@raps.org